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Platelet-activating factor-induced loss of glomerular anionic charges.
The urinary protein excretion rate, the glomerular localization of
cationic proteins (CP) derived from platelets and polymorphonuclear
neutrophils (PMN) and the loss of fixed anionic charges were studied in
rabbits infused with synthetic I-0-octadecyl-2-acetyl-sn-glyceryl-3-
phosphorylcholine [platelet activating factor (PAF), 1.5 1kg/kg in 2 ml of
saline containing 0.25% bovine serum albumin (BSA)). The urinary
protein excretion rate, unaffected by diphenhydramine, an antihista-
minic agent, reached its maximum at 180 mm and decreased 24 hr after
PAF infusion. The localization of CP derived from platelets and PMN
was investigated by immunofluorescence using specific antisera. Plate-
let-derived CP were detectable in glomeruli at 15 mm and, particularly,
at 180 mm after PAF infusion. Cells positive for CP derived from PMN
accumulated within 15 mm in the glomerular capillaries and, later (180
mi, cytoplasmic depletion and localization in glomerular capillary
walls occurred. CP deposits were associated with the loss of fixed
anionic charges as detected by ruthenium red and colloidal iron
staining. Rabbits infused with l-0-octadecyl-sn-glyceryl-3-phosphoryl-
choline (lyso-PAF) or saline-BSA alone had none of the alterations
described above. The development of proteinuria, the glomerular
localization of platelet- and PMN-derived CP and the concomitant loss
of fixed anionic charges suggested the possibility that, once CP were
released in the circulation from PAF-stimulated platelets and PMN,
they bound to, and neutralized, fixed anionic charges, resulting in
enhanced glomerular permeability.
Perte des charges anioniques après l'injection du facteur activant les
plaquettes. Aprés l'injection du l-0-octadecyl-2-acetyl-sn-glyceryl-3-
phosphorylcholine synthetique (platelet activating factor, PAF) (1.5
g/kg en 2 ml de solution saline contenant 0.25% d'albumine serique
bovine, BSA), on notait une thrombocytopénie et une neutropénie.
Apparaissait une augmentation d'excrétion protéique urinaire non
modifiée par le traitement préalable avec difénidramine qui était
maximale a 180 mm et diminuée 24 hr après l'injection de PAF. La
localisation glomerulaire des proteins cationiques (CP) des plaquettes et
des neutrophiles polynuclCaires (PMN) a etée étudiée par l'immuno-
fluorescence a l'aide d'antisériques specifiques de chCvre. Les CP des
plaquettes apparaissaient déjà après 15 mm et, surtout, aprés 180 mm
l'injection de PAF. L'étude de Ia localisation des CP dérivées des PMN
révélait une accumulation précoce (15 mm) des cellules positives dans
les glomerules et a 180 mm on remarquait Ia depletion cytoplasmatique
et la localisation des CP sur les capillaires glomerulaires. Les dépôts
glomerulaires des CP étaient lies a Ia perte des charges anioniques
comme avérée par Ia nette reduction de Ia coloration de ruthenium
rouge et du fer colloidal. Chez les lapins injectés avec le 1-0-octadecyl-
sn-glyceryl-3-phosphorylcholine (lyso-PAF) ou avec La solution saline-
BSA seulment, on ne notait aucune alteration des comptes cellulaires,
de l'excretion protéique urinaire, ni aucun dépôt glomerulaire de CP et
une distribution normale des charges anioniques. La presence de
protéinurie, les dépôt des CP des plaquettes et des PMN le long de Ia
paroi capillaire glomerulaire ainsi que Ia perte simultanée des charges
anioniques suggerent que les CP, libérées dans le cercle par plaquettes
et PMN stimulés par le PAF, pouvaient neutraliser les charges anioni-
ques avec, pour résultat, une augmentation de Ia perméabilite
glomerulaire.
Acute, "one-shot" serum sickness glomerulonephritis in the
rabbit is considered as an experimental model of tissue injury
induced by local deposition of immune complexes, which, at
least in part, are primarily formed in the circulation [1—3].
Deposition in tissues of circulating immune complexes has been
related to several factors (for review, see [4]), including the
release of vasoactive mediators from platelets [5—71. In rabbit
acute serum sickness, platelet activation is mediated by a polar
lipid released from sensitized basophils, originally described as
platelet-activating factor (PAF) [8] and recently characterized
as an acetyl glyceryl ether phosphorylcholine [9—11]. A broad
range of biological activities (for review, see [12]) has been
reported, including the capacity to induce a transient increase in
cutaneous vascular permeability [131. In rabbit acute serum
sickness, the deposition or the formation of immune complexes
in glomeruli is preceded by intravascular release of PAF from
basophils [14]. However, direct evidence that PAF is implicated
in increasing permeability of the glomerular capillary wall and
favors local deposition or formation of immune complexes is
still lacking.
The glomerular capillary wall functions as a size- and charge-
selective barrier [15, 16]; the distribution and nature of fixed
anionic charges is now well established [17—191. Glomerular
perfusion with exogenous polycations induces proteinuria,
spreading of foot processes, obliteration of slit pores, and loss
of fixed anionic charges [20], suggesting that fixed anionic
charges not only condition glomerular permeability to anionic
molecules, but also maintain, by electrostatic repulsive forces,
the structural organization of the foot processes [20]. In several
models of experimental glomerular injury, the loss of fixed
anionic charges precedes the onset of proteinuria, suggesting
that neutralization [21, 22] or destruction [23] of fixed anionic
charges leads to a charge-selective increase in permeability.
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Moreover, deposition or formation of immune complexes in the
glomerular capillary wall appears to be associated to or preced-
ed by a redistribution and/or a loss of fixed anionic charges [24].
Recent studies indicate that the localization of endogenous
cationic proteins (CP) in the glomerular capillary wall is con-
comitant with the loss of fixed anionic charges and development
of proteinuria [25]. CP released from platelets, polymorphonu-
clear neutrophils (PMN), and macrophages could possibly be
responsible for neutralization or destruction of fixed anionic
charges during the course of a glomerular inflammatory
reaction.
The present study was designed to test the hypothdsis that
PAF may exert a role in the development of glomerular
proteinuria that occurs during immunologically mediated in-
flammatory reactions. The results obtained show that PAF
infusion into the abdominal aorta of rabbits induces a reversible
proteinuria, associated with glomerular localization of platelet-
and PMN-derived CPconcomitant with the loss of fixed anionic
charges.
Methods
Buffers. The composition of buffers used is as follows:
Tyrode's(T): KCI, 2.6 mM; MgCI26H2O, 1.0 mM; NaCI, 137.0
mM; NaHCO3, 10.0 mM; CaCI26H2O, 3.0 mM; glucose, 0.1%;
Tris-buffered Tyrode's (TI'): Tyrode's with Tris (hydroxymethyl
aminomethane), 1.0 m used instead of bicarbonate. When
indicated, 0.25% bovine serum albumin (BSA, Fraction V,
Eurobio, Paris, France) was added to TT (TT-BSA). Unless
otherwise stated, buffers were adjusted to pH 7.4. When
calcium and magnesium ions were omitted in TT-BSA, the
latter was designated as TT-BSA no Ca2, no Mg2. Saline-
BSA consisted of sterile physiologic saline supplemented with
0.25% BSA.
Stimuli. Synthetic I -0-octadecyl-2-acetyl-sn-glyceryl-3-phos-
phorylcholine (synthetic platelet activating factor, PAF) (Ba-
chem Feinchemikalien AG, Bubendorf, Switzerland) was dis-
solved as stock solution in chloroform-methanol (2:1, v/v) (I
mg/mi) and, before use, in saline-BSA, with BSA acting as PAF
carrier $1. Synthetic I -0-octadecyl-2-acetyl-sn-glyceryl-3-phos-
phorylcholine was characterized as PAF on the basis of the
following criteria: (I) ability to induce rabbit platelet aggrega-
tion, which was unaffected by indomethacin (10 LM, Sigma
Chemical Company, St. Louis, Missouri) and ADP scavengers
(creatine phosphate, 312.5 g/ml .-creatine phosphokinase,
152.5 g/ml, enzymatic system, Sigma Chemical Company [26];
(2) physicochemical characteristics [27, 28]; (3) migratory prop-
erties on thin layer chromatography (TLC) on glass plates
precoated with silica gel (60F254, Merck, Darmstadt GmbH,
Federal Republic of Germany) (solvent system: chloroform-
methanol-water, 65:35:6, v/v, Rf:0.22) [281; and (4) sensitivity
to phospholipase A2 from porcine pancreas (0.03 mg/mI, Boeh-
ringer-Mannheim GmbH, Federal Republic of Germany) after
incubation for 1 hr at 37°C in TT-BSA, pH 8.0 [29]. The lyso-
derivative of PAF, I -0-octadecyl-sn-glyceryi-3-phosphorylcho-
line (lyso-PAF), functionally inactive on washed rabbit plate-
lets, was obtained after incubation with 0.5 N NaOH in metha-
nol, purified by TLC (solvent system: chloroform-methanol-
water, 65:35:6, v/v, Rf: 0.15) [28], and finally suspended in
saline-BSA.
Animals. New Zealand White rabbits of either sexes, weigh-
ing 2.5 to 3 kg, were used for these studies.
Experimental procedures
A saline-filled polyethylene sterile intravenous catheter (H.
G. Wallace, Cochester, United Kingdom) with a diameter of
1.14 mm was placed into the abdominal aorta of rabbits
anesthetized with sodium pentobarbitai (approximately 10
mg/kg). Three sets of experiments were performed: (1) Thirteen
rabbits were infused with PAF (five rabbits) or lyso-PAF (four
rabbits) (1.5 tg/kg) in 2 ml of saline-BSA or with saline-BSA
alone (2 ml, four rabbits) over a 15-sec period. Samples of
citrated (3.8% trisodium citrate) blood (1:9, v/v) were drawn
before and 30 sec, 1, 2, 3, 4, 5, 10, 30, and 60 mm after the
infusion of PAF, lyso-PAF, or saline-BSA. Platelet and PMN
counts were performed on a Malassez hemocytometer chamber
(volume: 1 mm3; depth: 0.2 mm. Preciss, Paris, France); (2) 20
rabbits were first volume-expanded to obtain constant urine
volumes, then infused with PAF, lyso-PAF, or saline-BSA to
evaluate the possible occurrence of proteinuria. In this experi-
mental setting, blood volume of rabbits was expanded over a
period of 20 mm with a quantity of isotonic saline equal to 10%
of the body weight according to the technique described by
Hunsicker, Shearer, and Shaffer [211 and modified in the rabbit
as follows: The bladder was catheterized using a sterile balloon
catheter with a diameter of 1.8 mm (Folatex, Eschman, Lon-
don, United Kingdom). Each rabbit was then permitted to
equilibrate for 120 mm with a continuous saline infusion deliv-
ered at a rate of 0.5 mI/mm, until three sequential 15-mm urine
collections yielded constant volumes approximately within
10%. After equilibration, 12 rabbits were infused with PAF (1.5
.tg!kg) in 2 ml of saline-BSA. Three of them were pretreated
with an antihistaminic agent by subcutaneous injection of
diphenhydramine (25 mg/kg, Benadryl®, Parke, Davis & Co.,
Detroit, Michigan), 15 mm before the challenge with PAF. In
preliminary experiments, this dose of diphenhydramine was
shown to abrogate histamine (1.5 to 10 g)-induced increase in
permeability in the skin vasculature of rabbits (2.5 to 3 kg)
injected intravenously with Evans' blue (1.0 mI/kg of a 5%
solution, Sigma Chemical Company). Four rabbits died 15 mm
after PAF infusion and were excluded from this study. Lyso-
PAF (1.5 pg/kg) in 2 ml of saline-BSA or saline-BSA alone (2
ml) were infused in three and five control rabbits, respectively.
In rabbits infused with PAF, but not with lyso-PAF or saline-
BSA, systemic hypotension developed within 30 to 45 sec as
indirectly shown by avascularity of the eyes and a significant
reduction of pulsatile blood flow from the catheter placed in the
abdominal aorta. The infusion of test materials was followed by
continuous saline infusion at a rate of 0.5 mI/mm. Sequential 15-
mm urine collections were obtained during the period of study
(180 mm). Volumes were determined by weight, assuming a
specific gravity of 1.0. In rabbits infused with PAF, but not with
lyso-PAF or saline-BSA, transient reduction in urine volume
(range, 0.06 to 0.1 mI/mm), possibly due to the hypotensive
effect of PAF [301, occurred in the first 30 mm after the end of
the infusion. Later, (60 mm after PAF infusion), the 15-mm
urine volume returned to constant amounts that were compara-
ble (range, 1 to 1 .5 mI/mm) to those collected during equilibra-
tion. Urinary protein excretion rate was also evaluated over a
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Table 1. Loss of glomerular-flxed anionic charges and deposit of CP derived from platelets and PMN in the glomerular capillary wall of rabbits
infused with PAF, lyso-PAF, and saline-BSA
No.
of
rab- Infused with
Time of
sacrifice
Quantitation glomerular anionic sites°
PMN index
Immunofluorescence
By
ruthenium red
No x m
GBM
% Loss of colloidal iron
staining
Anti-CP" from PMN AntiCP"
from
platelets
(+)
GCW
Cell index (+)Total Segmental
bits
4 PAF 15 mm 50.0 19.0 0 11.0 6.5 4.4 2.l' 4.4 2.0° 0.3 0.4 1.5 0.9
3 PAF 60 mm 18.6 3.0 1.0 1.0 56.6 14.1 3.5 0.6 0.7 0.6 1.3 0.7 1.8 0.2
4 PAF 180 mm 9.2 10.8 9.7 12.2 59.5 12.6 2.8 0.5 0.5 0.4 2.3 0.9 2.3 0.4
4 PAFC 180 miii 9.0 9.6 9.5 10.7 60.7 10.4 2.7 0.8 0.4 0.5 2.2 0.8 2.2 0.6
3 PAF 24 hr 14.9 6.3 3.6 2.8 55.3 11.6 1.2 0.2 0.1 0.1 0.6 0.3 1.1 0.3
3 Lyso-PAF 180 mm 54.2 12.0 0 6.2 3.3 0.1 0.1 0.1 0.1 0 0.1 0.3
3 Lyso-PAF° 180 mm 55.1 11.8 0 6.1 4.1 0.1 0.2 0.1 0.1 0 0.1 0.2
3 Saline-BSA 15 mm
3 Saline-BSA 60 mm 59.5 9.1 0.5 1.3 3.7 4.8 0.07 0.09 0.06 0.1 0 0
3 Saline-BSA 180 mm
3 Saiine-BSA 180 mm
Glomerular anionic sites were studied by electron microscopy using ruthenium red following the technique of Kanwar and Farquhar [37] and by
light microscopy with the colloidal iron staining method [381. In experiments using ruthenium red, results were expressed as the number of
glomerular anionic sites counted in a l-m length of glomerular basement membrane (GBM). In experiments with colloidal iron staining technique,
the results were expressed as the percentage of glomeruli with either total or segmental loss of glomerular anionic sites on the total number of
glomeruli.
Deposits of CP antigens were detected by indirect immunofluorescence using specific (see Methods) goat antisera and fluorescein-conjugated
rabbit anti-goat y globulin as the second layer. GCW represents glomerular capillary wall.
These rabbits were volume-expanded (as detailed in Methods).
d These numbers were derived from the following formula: number of untraglomerular PMN/number of glomeruli.
These numbers were derived from the following formula: number of intraglomerular CP-positive cells/number of glomeruli.
Means I SD.
period of 120 mm after volume expansion and equilibration (as
detailed above) in five rabbits 24 hr after PAF infusion. Urinary
protein excretion rate was determined either by quantitative
nephelometry after protein precipitation in trichloroacetic acid
(final concentration, 5%) or by the Ponceau red S method.
Crystallized BSA (Behringwerke, Marburg, Federal Republic
of Germany) was used as standard. (3) In a third set of
experiments, 36 rabbits were used to study the amount of fixed
anionic charges, the intraglomerular accumulation of PMN, the
deposits of platelet- and PMN-derived CP in the glomerular
capillary wall at different time intervals after the infusion of
PAF (14 rabbits without and four with volume expansion), of
lyso-PAF (three rabbits without and three with volume expan-
sion) and of saline-BSA (nine rabbits without and three with
volume expansion) (Table I). At the time of death (three rabbits
died 15 mm after PAF infusion) or at sacrifice (15, 60, 180 mm
or 24 hr after challenge), the right kidney was excised and
processed for light and immunofluorescence microscopy. The
contralateral kidney, once exposed, was perfused as described
in the section Histological and immunopathological studies of
renal tissue.
Preparation of cells
Rabbit blood, obtained from the central artery of the ear, was
collected in siliconized 50-mi plastic tubes, containing 5 mM
(final concentration) of EDTA, pH 7.2. After centrifugation
(x350g, 20 mm), blood separated into three layers: platelet-rich
plasma, buffy coat, and PMN plus erythrocytes. Washed plate-
lets were prepared according to the method of Ardlie, Packham,
and Mustard [31] and slightly modified by the addition of a final
low-speed (x30g, 15 mm) centrifugation to eliminate contami-
nating leucocytes. Less than 0.01% leucocytes were present in
our platelet preparations. The latter were stored at —80°C in
distilled water. PMN were prepared according to the method of
Lynch et al [32]. Platelet contamination was less than 1%. Pure
PMN (95 to 99%) were resuspended in distilled water and stored
at —80°C. Washed rabbit platelets prepared according to Ardlie,
Packham, and Mustard [31] were also used to assess PAF
activity by aggregometry [8].
Purification of rabbit CP
PMN-derived CP. PMN sonicates, pooled from several prep-
arations, were acidified with 2 N H2S04, neutralized with I N
NaOH according to Ranadive and Cochrane [33], and lyophi-
lized. Sequential ion-exchange (DEAE-Sepharose CL 6B, Phar-
macia Fine Chemicals AB, Uppsala, Sweden) and gel filtration
(Sephadex G-50, Pharmacia) chromatography was used for
purification of PMN-derived CP [33]. By polyacrylamide gel
electrophoresis (gel concentration: 15%) performed in 0.05 M
Tris-glycine buffer, pH 8.6, at 100 V and 30 to 40 mA, four basic
components of PMN-derived CP could be resolved with a
molecular weight ranging from 4,000 to 24,000 daltons as
elsewhere reported [33]. Isoelectric points were determined by
chromatofocusing [34] using a column (1.6 x 40cm, Pharmacia)
packed with PBE 94 (Pharmacia) equilibrated with 25 mtvi
ethanolamine-HCJ, pH 9.4. Four peaks were resolved by elu-
tion with Pharmalyte (Pharmacia), pH 8.0, at the following pH:
9.4, 9.3, 9.25, and 9.15. PMN-derived CP displayed vasoper-
meabilizing properties in the skin of rabbits preinjected (see
above) with Evans' blue (minimal effective dose: 1 pg), the
capacity to induce in vitro basophil degranulation as tested by
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Fig. l.A Fluorescence micrographs of rabbit peripheral blood smears stained with fluorescein-conjugated serum from goat immunized to CP
derived from rabbit PMN. IdentifIcation of the cell type was obtained by nuclear staining with ethidium bromide and phase contrast microscopy.
PMN gave an intense, green-colored, granular cytoplasmic staining. Erythrocytes, present in the preparation, were not stained and not visible. The
cytoplasm of lymphocytes (arrow) and mononuclear cells (not shown) were negative; only the nuclei were stained bright red. (x360) B
Fluorescence micrographs of smears of platelet-rich plasma stained with fluorescein-conjugated goal antiserum against CP derived from rabbit
platelets. (x360) A and B are representative of nine experiments.
the technique of Benveniste et al [351 (minimal effective dose:
0.1 g) and to contract isolated ileal smooth muscle [33]
(minimal effective dose: 0.3 pg).
Platelet-derived CP. Platelet-derived CP were obtained from
rabbit platelets purified as described above, after sonication of
cells, extraction of lysosomal granules by diluted H2S04 and
lyophilization of the neutralized extracts according to Nach-
man, Weksler, and Fabris [36], and as described above for the
preparation of PMN-derived CP. Separation of platelet-derived
CP was accomplished by ion-exchange and gel filtration chro-
matography using sequentially DEAE Sepharose CL 6B and
Sephadex G-50 (Pharmacia) columns in the same experimental
conditions as outlined by Ranadive and Cochrane [33]. Four
bands were resolved in a range of molecular weights within
14,000 and 45,000 daltons by polyacrylamide gel electrophore-
sis (see above). Four peaks were eluted from a chromatofocus-
ing column (see above) at the following pH: 9.4, 9.0, 8.7, and
8.5. Platelet-derived CP induced an increase in vascular perme-
ability in the skin of rabbits pretreated (see above) with Evans'
blue (minimal effective dose, I .tg) and in vitro basophil
degranulation as tested by the technique of Benveniste et al [35]
(minimal effective dose, 0.1 tg).
Preparation of goat anti-rabbit sera to PMN- and platelet-
derived CP
The antigenic inoculum used to immunize the goats was
obtained by pooling several homogenous preparations of PMN-
and platelet-derived CP. Antisera were raised in two goats by
the same immunization protocol described in detail by Camussi
et al [25]. The specificity of the antisera was established as also
described by Camussi et al [25]. Briefly, the ammonium sul-
phate, y globulin-rich serum fractions were sequentially ab-
sorbed (30 mm, at room temperature and overnight at 4°C) with
the following substrates: platelet-poor plasma, erythrocytes,
purified platelets, lymphocytes, monocytes pooled from several
rabbits, for the antiserum to PMN-derived CP; platelet-poor
plasma, erythrocytes, PMN, lymphocytes and monocytes for
the antiserum to platelet-derived CP. The antisera were either
labeled with fluorescein isothiocyanate (Miles Laboratories,
Elkart, Indiana) or used as such in experiments of indirect
immunofluorescence, using a fluoresceinated rabbit anti-goat y
globulin serum (Cappel Laboratories, Cochranville, Pennsylva-
nia). The antisera against PMN- and platelet-derived CP were
able to react with cytoplasm of rabbit PMN (Fig. lA) or
platelets (Fig. 1B). No cross-reactivity with rabbit erythrocytes,
lymphocytes, mononuclear cells in peripheral blood smears, or
with purified plastic-adherent monocytes was observed. By
immunofluorescence, the antiserum did not react with normal
rabbit kidney. However, cross-reactivity with platelets existed
for the antisera to PMN and platelet-derived CP, respectively.
Absorption studies with purified platelets abolished the cross
reactivity with the antiserum to PMN-derived CP. Conversely,
absorption of the antiserum to platelet-derived CP abolished
cross-reactivity with PMN.
Histological and immunopathological studies of renal tissue
The left kidney was exposed and perfused as described by
Kanwar and Farquhar [371, with a 0.2% solution of ruthenium
red, used to detect fixed anionic charges, in Karnowsky aide-
hyde fixative. Fixed anionic charges were quantitated by count-
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ing the granular electron-dense deposits distributed in quasi-
regular network in the laminae rarae interna and externa of the
glomerular basement membrane on at least 20 electron micro-
graphs taken at random at constant magnification (x40,000).
Results were expressed as the number of anionic sites counted
in 1 tm length of glomerular basement membrane (Table 1).
The right kidney was divided into two parts, one of which was
used for light and the other for immunofluorescence microsco-
py. Tissue for light microscopy was fixed in 10% buffered
formalin and embedded in paraffin. Sections, 4 to 5 m in
thickness, were stained with hematoxylin and eosin, periodic
acid-Schiff(PAS) reagent, and the colloidal iron staining tech-
nique [381, as previously described by Camussi et a! [25]. The
intensity and extent of colloidal iron staining were evaluated
semiquantitatively and expressed as the percentage of glomeruli
that exhibited segmental or total loss of fixed anionic charges
(Table 1). As control, duplicate sections from each specimen
were not exposed to colloidal iron but were processed with
HCI-potassium ferrocyanide to rule out nonspecific staining due
to naturally occurring hemosiderin [38]. Immunofluorescence
studies were performed on renal tissue snap-frozen in liquid
nitrogen. Sections, 2 to 4 m in thickness, were obtained in a
cryostat. After the sections were washed in phosphate buffer
0.1 M, NaCI 0.15 M, they were incubated with goat anti-
rabbit PMN- and platelet-derived CP and indirect immunofluo-
rescence was performed using a fluoresceinated rabbit anti-goat
y globulin serum (Cappel Laboratories) as a second layer. The
latter antiserum did not stain the renal sections from normal and
PAF-infused rabbits. A minimum of 20 glomeruli from each
section was examined. The intensity and extent of the fluores-
cence staining for PMN- and platelet-derived CP antigens on
glomerular capillary walls were arbitrarily graded from 0 to 3+.
The number of cells positive for PMN- derived CP present in
the glomeruli was expressed as "cell index," indicating the
total number of fluorescent cells divided by the number of
glomeruli. When PMN- and platelet-derived CP antigens were
detected, contiguous sections were incubated with the corre-
sponding antiserum previously absorbed with purified CP de-
rived from PMN or from platelets, to assess the specificity of
the reaction. PMN present in the glomeruli of sections stained
with hematoxylin-eosin were counted. The results were ex-
pressed as the PMN index," resulting from the total number
of intraglomerular PMN, divided by the number of glomeruli.
Quantitation of histological and immunohistological parameters
was evaluated by two independent observers, and the results
were given as the means of the findings.
Results
A marked, acute reversible thrombocytopenia and neutrope-
nia (99.3 0.5 and 99.1 0.3%, mean 1 SD of prechallenge
platelet and PMN counts, respectively) occurred 30 sec after
the end of PAF infusion. Platelet and PMN counts returned to
prechallenge values within 60 mm. No significant fall in platelet
and PMN counts was seen after the infusion of lyso-PAF or
saline-BSA.
In five rabbits, which had been volume-expanded, the urinary
protein excretion rate increased starting from 30 mm, reached
its maximum at 180 mm and was reduced markedly 24 hr after
the end of PAF infusion (Fig. 2). No variation in urinary protein
excretion rate was observed in rabbits infused with lyso-PAF
Fig. 2. Effect of the intravenous infusion of PAF on urinaly protein
excretion rate. Rabbits were allowed to equilibrate for 120 mm after
volume expansion (see Methods). Five rabbits (•) were infused over a
15-sec period with PAF (1.5 pg/kg in 2 ml of saline-BSA); three of these
rabbits (A) were subcutaneously injected with diphenhydramine (25
mg/kg) 15 mm before PAF infusion. As control, lyso-PAF (— —) (1.5
.tg/kg in 2 ml of saline-BSA or saline-BSA alone ( ) (2 ml) were
infused in three and five rabbits, respectively. Mean 1 su (I).
(three rabbits) or with saline-BSA (five rabbits). In three
rabbits, pretreatment with diphenhydramine could not prevent
the occurrence of proteinuria after PAF infusion.
In other experiments using 36 rabbits infused with PAF (14
rabbits without and four with volume expansion), lyso-PAF
(three rabbits without and three with volume expansion) or
saline-BSA (nine rabbits without and three with volume expan-
sion), the amount of fixed anionic charges, the intraglomerular
accumulation of PMN, the deposits of PMN- and platelet-
derived CP in the glomerular capillary wall were evaluated
(Table 1). It can be seen that in rabbits injected with lyso-PAF
or saline-BSA, the pattern of distribution of ruthenium red was
uniform along the glomerular capillary wall and characterized
by granular, electron-dense deposits distributed almost at a
regular distance from each other (Fig. 3A). The glomeruli of all
these control rabbits were stained regularly by colloidal iron.
Deposits of platelet- and PMN-derived CP were never ob-
served. In contrast, in rabbits sacrificed 60 mm and particularly
180 mm after the end of PAF infusion, granular, electron-dense
deposits of ruthenium red in the laminae rarae interna and
externa were smaller in size and reduced in number (Fig. 3B and
C). The reduction of fixed anionic charges as detected by
ruthenium red persisted at 24 hr. Three rabbits died and one
was sacrificed 15 mm after the end of PAF infusion, No
variation in morphology and quantity of deposits of ruthenium
red were observed 15 mm after infusion of PAF, lyso-PAF, or
saline-BSA (Table 1). The loss of fixed anionic charges in the
glomerular capillary wall in rabbits sacrificed 60 or 180 mm or
24 hr after the end of PAF infusion was confirmed by the
segmental reduction of colloidal iron staining in tissue sections
examined by light microscopy. Deposits of CP derived from
platelets were detected in the glomerular capillary wall as early
I
100
50
I
180 mm hr15 1.—— +-1—30
Time
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glomerular deposits of CP derived from platelets had a segmen-
tal, prevalently linear pattern of distribution along the glomeru-
lar capillary wall (Fig. 4B). Interestingly, there was a simulta-
neous segmental, linear localization of platelet-derived CP
along the peritubular capillaries. Fifteen minutes after the end
of PAF infusion, cells positive for PMN-derived CP were
identified in the glomeruli by immunofluorescence (Fig. 4C).
Their number corresponded to that of PMN detected in tissue
sections stained with hematoxylin-eosin. Concurrently, depos-
its of PMN-derived CP were not detectable in the glomerular
capillary wall. The number of cells positive for PMN-derived
CP in glomeruli markedly diminished at 60 and 180 mm after
PAF infusion (Table 1). At this time, although the PMN index
decreased from an average of 4.4 to 2.8, this reduction was not
as dramatic as that seen in the CP-positive cell index (Table I).
At this very time, however, deposits of CP derived from PMN
were present in the glomerular capillary wall with a segmental,
linear pattern similar to that of CP from platelets (Fig. 4D).
Discussion
Fig. 3. PAF-infused and control rabbits. Electron micrographs of renal
tissue stained with ruthenium red. A Electron-dense, granular deposits
of ruthenium red in control rabbits seen along the laminae rarae interna
and externa (arrows). (x51,600) B Sixty minutes after the end of PAF
infusion. (x51,600) C One hundred and eighty minutes after the end of
PAF infusion. (X51,600) In both B and C, there occurred a marked
reduction of ruthenium red binding in the laminae rarae interna and
externa.
as 15 mm after the end of PAF infusion. At this time, immuno-
fluorescence distribution was evidenced either as granule de-
posits within the lumina of glomerular capillaries or as inter-
rupted, linear deposits along the glomerular capillary wall (Fig.
4A). Sixty and 180 mm and 24 hr after PAF infusion, the
The results of the present study indicate that, in rabbits
infused with PAF, a reversible proteinuria occurs concomitant
with the deposit of platelet- and PMN-derived CP antigens in
the glomerular capillary wall and with loss of fixed anionic
charges.
PAF has been shown to possess a potent cutaneous vasoper-
meabilizing effect, which is not reduced by antihistamines [13].
PAF-induced enhanced vascular permeability may be ascribed
either to the release of secondary nonhistaminic mediators from
stimulated target cells (platelets, PMN, monocytes) or to a
direct effect on the walls of vessels or on endothelial cells.
In the present study, PAF induced a mild increase in glomer-
ular permeability with consequent proteinuria that started at 30
mm, reached its peak after 60 to 180 mm and was markedly
reduced 24 hr after the end of PAF infusion. Since pretreatment
of rabbits with diphenhydramine, an antihistaminic agent, did
not prevent the occurrence of proteinuria after PAF infusion,
the role of endogenous histamine as mediator of increased
glomerular permeability appears unlikely. This effect of PAF on
glomerular permeability could have been related to its biologi-
cal activity, since its inactive derivative, lyso-PAF, was unable
to induce proteinuria.
PAF, but not lyso-PAF, injected intravenously into rabbits,
has been shown to elicit a spectrum of cardiovascular, pulmo-
nary, and hematological changes similar to those observed in
anaphylactic shock [121. Dose-dependent, acute, reversible
thrombocytopenia and neutropenia have been related to the
massive formation of platelet and PMN aggregates in the
peripheral capillary network [39]. These intravascular events
occur simultaneously with the release of lysosomal constituents
from platelets and PMN. Stimulated platelets and PMN liberate
cationic mediators such as platelet factor 4 (PF4), /3-thrombo-
globulin [40, 41], lysozyme, and cathepsins [42], respectively.
Stimulated platelets and PMN also release CP, which possess
vasopermeabilizing effects [36, 33].
In the present study, the concomitant deposit of CP antigens
derived from platelets and PMN in the glomerular capillary wall
and the loss of fixed anionic charges are consistent with the
hypothesis that CP may bind to and neutralize fixed anionic
charges. The deposit of CP antigens derived from platelets
Y'c
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occurred as early as 15 mm after PAF infusion either as granule
deposits within the lumina of glomerular capillaries or as
interrupted, linear deposits along the glomerular capillary wall,
a pattern that became more evident 60 and 180 mm after PAF
infusion. Cells positive for PMN-derived CP accumulated in
glomeruli 15 mm after the end of PAF infusion. At this time,
deposits of PMN-derived CP were not detectable in the glomer-
ular capillary wall. Sixty to 180 mm after PAF infusion, the
number of PMN-derived CP-positive cells in glomeruli dimin-
ished more markedly than the number of PMN themselves as
detected by light microscopy, indicating that degranulation,
with depletion of CP, might have occurred. Concurrently to this
reduction, segmental, linear deposits of PMN-derived CP ap-
peared in the glomerular capillary wall. Fixed anionic charges
were reduced at 60 mm and, more markedly, at 180 mm after
PAF infusion. These findings support the interpretation that
PAF-induced PMN aggregation and subsequent accumulation
in glomerular capillaries is followed by degranulation and
release of CP, which may then bind to fixed anionic charges of
the glomerular capillary wall.
The apparent discrepancy between the early glomerular
localization of CP (15 mm) and the increase in urinary protein
excretion rate, that occurred only after 60 to 180 mm after PAF
infusion, could be explained either by the delayed release of
cationic mediators from cells entrapped in glomeruli, as inferred
from the kinetics of accumulation and degranulation of PMN, or
by the time that elapses between glomerular filtration and urine
collection in the bladder. The delayed detection of proteinuria
Fig. 4. Immunofluorescence micrographs of glomerulifrom rabbits infused with PAF and sacnficed 15 mm (A) and (C) and 180 mm (B and D) after
infusion. The sections of renal tissue were stained with fluorescein-conjugated antisera to CP derived from rabbit platelets (A and B) and PMN (C
and D). A Deposits of platelet-derived CP antigens present at 15 mm after the end of PAF infusion either as granule deposits in the capillary lumina
or as interrupted, linear deposits along the glomerular capillary wall. (x368) B One hundred and eighty mm after the end of PAF infusion, the
glomerular deposits of platelet-derived CP antigens with prevalently linear, segmental distribution along the glomerular capillary wall. The
cytoplasm of the epithelial cells was faintly stained. (xl, 100) C Cells positive for PMN-derived CP antigens detected in glomeruli 15 mm after the
end of PAF infusion. (x368) DOne hundred and eighty mm after the end of PAF infusion, few cells positive for PMN-derived CP remained in the
glomeruli. However, deposits of PMN-derived CP antigens were present with a linear, segmental pattern. (x550; Inset, x920)
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might also be related to the marked reduction in urine volume
during the first 30 mm after infusion, possibly due to the
hypotensive effect of PAF. Halonen et at [301 reported an early
(2 mm) and late (3 to 9 mm) decrease in aortic pressure that
reached its lowest value (31% of prechallenge level) within 9
mm after PAF infusion and took at least 15 mm to return to
baseline values. Severe shock secondary to this marked hypo-
tensive action of PAF might be responsible for ischemia or
altered hemodynamics which could induce changes in the
glomerular capillary wall, possibly explaining the observed,
transient proteinuria. In addition, ischemia may result from the
entrapment of PMN and platelet aggregates in glomeruli.
In conclusion, although the present study demonstrates that
after PAF infusion, there is a localization of CP derived from
platelets and PMN in the glomerular capillary wall as well as a
concomitant loss of fixed anionic charges, further studies are
needed to discriminate primary and secondary events involved
in PAF-induced alteration of glomerular permeability.
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